Abstract
Using the example of the recently reported phase III MAIA trial, we emphasize herein the requirement to dig deeper into trial designs and end points to determine their appropriateness for the questions at hand and to assess whether a benefit in terms of the primary end point — even if statistically significant and seemingly clinically meaningful — is sufficient to warrant a change in clinical practice.
Original language | English (US) |
---|---|
Pages (from-to) | 339-340 |
Number of pages | 2 |
Journal | Nature Reviews Clinical Oncology |
Volume | 16 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2019 |
ASJC Scopus subject areas
- Oncology